Exelixis and Merck Establish Chemistry Collaboration
Companies Combine Chemistry Expertise to Create Novel Libraries
"Exelixis has achieved broad recognition for its excellence in target identification and validation. This collaboration with Merck, together with our prior chemistry- based collaborations, is a tangible demonstration of the quality of our chemistry programs as well. This collaboration is expected to provide both our companies with enhanced combinatorial chemistry programs and screening libraries," said George A. Scangos, Ph.D., Exelixis president and chief executive officer. "Small molecule drug discovery today requires an integrated technology platform that combines novel biology with high quality, high throughput chemistry. We believe that this collaboration has the potential to advance both companies' strategies to achieve more diversity and depth in compound library design and production, generate more reliable lead compounds, and bring greater efficiency and productivity to the search for important new medicines."
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.